Aethon Therapeutics to Share Preclinical and Discovery-Stage Updates on KRAS-G12C Hapten-Peptide Immunotherapies at AACR 2025
New York, April 21, 2025 — Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, will present updates on its programs in oral and poster presentations at the American Association of Cancer Research (AACR) Annual Meeting taking place April 26-30, 2025, in Chicago, Illinois.
Aethon will also participate in a showcase session at the pre-conference Oncology Industry Partnering event on April 24 at the McCormick Place Convention Center in Chicago, featuring research highlights across programs and an overview of the company’s pipeline.
Details of Aethon’s AACR Annual Meeting 2025 presentations are as follows:
Oral Presentation
Mini symposium session: Antigens, Antibodies, BiTEs, and Vaccines
Date and time: 4/28/2025 2:30-4:30PM
Location: Room S102 – McCormick Place South
Title: Cross-HLA targeting of synthetic neoepitopes with T cell engagers to eradicate sotorasib-resistant, KRAS-G12C mutant cancer
Presenter: Lauren Stopfer, Ph.D., Executive Director of Proteomics & Innovation, Aethon Therapeutics
Poster Presentation
Session: PO.ET01.01 – Antireceptors and Other Biological Therapeutic Agents
Date and time: 4/27/25 2:00-5:00PM
Location: Poster Session, Section 15, 310
Title: Deciphering the molecular basis for pan-HLA recognition of divarasib-modified pMHCs by newly discovered hit-to-lead antibody AETX-R302
Presenter: Lorenzo Maso, Ph.D., Principal Scientist, Aethon Therapeutics
AACR Oncology Industry Partnering Event
Location: McCormick Place Convention Center West Building, W196
Date and time: 4/24/25 4:30-5:35 PM
Showcase Session 1: Aethon Therapeutics
Presenter: Sean Toenjes, Ph.D., Executive Director of Chemistry & Innovation, Aethon Therapeutics
About Aethon Therapeutics
Aethon Therapeutics creates neoantigens by design, to transform cancer treatments into cures. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies are designed to be used in combination with targeted covalent inhibitors of KRAS, EGFR, and other oncogenic driver mutations to mount immune attacks to selectively kill residual cancer cells, including drug-resistant “persister” cells. Co-founded in 2022 by venture capital firm Apple Tree Partners with New York University cancer researchers Shohei Koide, Ph.D. and Benjamin G. Neel, M.D., Ph.D., Aethon unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. For more information, visit aethontx.com
